Skip to main content
Top
Published in: Cardiovascular Toxicology 3/2010

01-09-2010

Comparison of the Effects of Methadone and Heroin on Human ether-à-go-go-Related Gene Channels

Authors: Bernd J. Zünkler, Maria Wos-Maganga

Published in: Cardiovascular Toxicology | Issue 3/2010

Login to get access

Abstract

Torsades de pointes (TdP) is a life-threatening form of ventricular arrhythmia that occurs under conditions of delayed cardiac repolarization indicated by prolonged QT intervals in ECG recordings. The main mechanism of QT prolongation and TdP is block of the rapid component of the cardiac delayed rectifier K+ current (IKr), which is encoded by hERG (human ether-à-go-go-related gene). The opioid agonist methadone has previously been demonstrated to inhibit hERG currents, and there are reports of serious cardiac arrhythmias and deaths from TdP and ventricular fibrillation in patients taking methadone. The aim of the present study was to compare the effects of the opioid agonists methadone and heroin (3,6-diacetylmorphine) on hERG currents stably expressed in human embryonic kidney (HEK 293) cells using the whole-cell configuration of the patch-clamp technique. Both methadone and heroin inhibit hERG currents in a concentration-dependent manner. The following values were calculated for IC50 (concentration causing half-maximal inhibition) and n (the Hill coefficient): 4.8 μM and 0.9 for methadone, 427 μM and 0.7 for heroin. In conclusion, the potency for block of hERG currents is about 100-fold lower for heroin when compared to methadone.
Literature
1.
go back to reference Keating, M. T., & Sanguinetti, M. C. (1996). Molecular genetic insights into cardiovascular disease. Science, 272, 681–685.CrossRefPubMed Keating, M. T., & Sanguinetti, M. C. (1996). Molecular genetic insights into cardiovascular disease. Science, 272, 681–685.CrossRefPubMed
2.
go back to reference Warmke, J. W., & Ganetzky, B. (1994). A family of potassium channel genes related to eag in Drosophila and mammals. Proceedings of the National Academy of Sciences of the United States of America, 91, 3438–3442.CrossRefPubMed Warmke, J. W., & Ganetzky, B. (1994). A family of potassium channel genes related to eag in Drosophila and mammals. Proceedings of the National Academy of Sciences of the United States of America, 91, 3438–3442.CrossRefPubMed
3.
go back to reference Sanguinetti, M. C., Jiang, C., Curran, M. E., & Keating, M. T. (1995). A mechanistic link between an inherited and an acquired cardiac arrhythmia. Cell, 81, 299–307.CrossRefPubMed Sanguinetti, M. C., Jiang, C., Curran, M. E., & Keating, M. T. (1995). A mechanistic link between an inherited and an acquired cardiac arrhythmia. Cell, 81, 299–307.CrossRefPubMed
4.
go back to reference Trudeau, M. C., Warmke, J. W., Ganetzky, B., & Robertson, G. A. (1995). hERG, a human inward rectifier in the voltage-gated potassium channel family. Science, 269, 92–95.CrossRefPubMed Trudeau, M. C., Warmke, J. W., Ganetzky, B., & Robertson, G. A. (1995). hERG, a human inward rectifier in the voltage-gated potassium channel family. Science, 269, 92–95.CrossRefPubMed
5.
go back to reference Recanatini, M., Poluzzi, E., Masetti, M., Cavalli, A., & De Ponti, F. (2005). QT prolongation through hERG K+ channel blockade: Current knowledge and strategies for the early prediction during drug development. Medicinal Research Reviews, 25, 133–166.CrossRefPubMed Recanatini, M., Poluzzi, E., Masetti, M., Cavalli, A., & De Ponti, F. (2005). QT prolongation through hERG K+ channel blockade: Current knowledge and strategies for the early prediction during drug development. Medicinal Research Reviews, 25, 133–166.CrossRefPubMed
6.
go back to reference Redfern, W. S., Carlsson, L., Davis, A. S., Lynch, W. G., MacKenzie, I., Palethorpe, S., et al. (2003). Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development. Cardiovascular Research, 58, 32–45.CrossRefPubMed Redfern, W. S., Carlsson, L., Davis, A. S., Lynch, W. G., MacKenzie, I., Palethorpe, S., et al. (2003). Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development. Cardiovascular Research, 58, 32–45.CrossRefPubMed
8.
go back to reference Katchman, A. N., McGroary, K. A., Kilborn, M. J., Kornick, C. A., Manfredi, P. L., Woosley, R. L., et al. (2002). Influence of opioid agonists on cardiac human ether-a-go-go-related gene K+ currents. Journal of Pharmacology and Experimental Therapeutics, 303, 688–694.CrossRefPubMed Katchman, A. N., McGroary, K. A., Kilborn, M. J., Kornick, C. A., Manfredi, P. L., Woosley, R. L., et al. (2002). Influence of opioid agonists on cardiac human ether-a-go-go-related gene K+ currents. Journal of Pharmacology and Experimental Therapeutics, 303, 688–694.CrossRefPubMed
9.
go back to reference Eap, C. B., Crettol, S., Rougier, J.-S., Schläpfer, J., Sintra Grilo, L., Deglon, J.-J., et al. (2007). Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers. Clinical Pharmacology and Therapeutics, 81, 719–728.CrossRefPubMed Eap, C. B., Crettol, S., Rougier, J.-S., Schläpfer, J., Sintra Grilo, L., Deglon, J.-J., et al. (2007). Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers. Clinical Pharmacology and Therapeutics, 81, 719–728.CrossRefPubMed
10.
go back to reference Krantz, M. J., Martin, J., Stimmel, B., Mehta, D., & Haigney, M. C. P. (2009). QTc interval screening in methadone treatment. Annals of Internal Medicine, 150, 387–395.PubMed Krantz, M. J., Martin, J., Stimmel, B., Mehta, D., & Haigney, M. C. P. (2009). QTc interval screening in methadone treatment. Annals of Internal Medicine, 150, 387–395.PubMed
11.
go back to reference Lin, C., Somberg, T., Molnar, J., & Somberg, J. (2009). The effects of chiral isolates of methadone on the cardiac potassium channel IKr. Cardiology, 113, 59–65.CrossRefPubMed Lin, C., Somberg, T., Molnar, J., & Somberg, J. (2009). The effects of chiral isolates of methadone on the cardiac potassium channel IKr. Cardiology, 113, 59–65.CrossRefPubMed
12.
go back to reference Hamill, O. P., Marty, A., Neher, E., Sakmann, B., & Sigworth, F. J. (1981). Improved patch-clamp techniques for high-resolution current recordings from cells and cell-free membrane patches. Pfluegers Archiv, 391, 85–100.CrossRefPubMed Hamill, O. P., Marty, A., Neher, E., Sakmann, B., & Sigworth, F. J. (1981). Improved patch-clamp techniques for high-resolution current recordings from cells and cell-free membrane patches. Pfluegers Archiv, 391, 85–100.CrossRefPubMed
13.
go back to reference de Vos, J. W., Geerlings, P. J., van den Brink, W., Ufkes, J. G., & van Wilgenburg, H. (1995). Pharmacokinetics of methadone and its primary metabolite in 20 opiate addicts. European Journal of Clinical Pharmacology, 48, 361–366.CrossRefPubMed de Vos, J. W., Geerlings, P. J., van den Brink, W., Ufkes, J. G., & van Wilgenburg, H. (1995). Pharmacokinetics of methadone and its primary metabolite in 20 opiate addicts. European Journal of Clinical Pharmacology, 48, 361–366.CrossRefPubMed
14.
go back to reference Romach, M. K., Piafsky, K. M., Abel, J. G., Khouw, V., & Sellers, E. M. (1981). Methadone binding to orosomucoid (alpha 1-acid glycoprotein): Determinant of free fraction in plasma. Clinical Pharmacology and Therapeutics, 29, 211–217.CrossRefPubMed Romach, M. K., Piafsky, K. M., Abel, J. G., Khouw, V., & Sellers, E. M. (1981). Methadone binding to orosomucoid (alpha 1-acid glycoprotein): Determinant of free fraction in plasma. Clinical Pharmacology and Therapeutics, 29, 211–217.CrossRefPubMed
15.
go back to reference Inturrisi, C. E., Colburn, W. A., Kaiko, R. F., Houde, R. W., & Foley, K. M. (1987). Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain. Clinical Pharmacology and Therapeutics, 41, 392–401.CrossRefPubMed Inturrisi, C. E., Colburn, W. A., Kaiko, R. F., Houde, R. W., & Foley, K. M. (1987). Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain. Clinical Pharmacology and Therapeutics, 41, 392–401.CrossRefPubMed
16.
go back to reference Benmebarek, M., Devaud, C., Gex-Fabry, M., Powell Golay, K., Brogli, C., Baumann, P., et al. (2004). Effects of grapefruit juice on the pharmacokinetics of the enantiomers of methadone. Clinical Pharmacology and Therapeutics, 76, 55–63.CrossRefPubMed Benmebarek, M., Devaud, C., Gex-Fabry, M., Powell Golay, K., Brogli, C., Baumann, P., et al. (2004). Effects of grapefruit juice on the pharmacokinetics of the enantiomers of methadone. Clinical Pharmacology and Therapeutics, 76, 55–63.CrossRefPubMed
17.
go back to reference Rook, E. J., Huitema, A. D. R., van den Brink, W., van Ree, J. M., & Beijnen, J. H. (2006). Population pharmacokinetics of heroin and its major metabolites. Clinical Pharmacokinetics, 45, 401–417.CrossRefPubMed Rook, E. J., Huitema, A. D. R., van den Brink, W., van Ree, J. M., & Beijnen, J. H. (2006). Population pharmacokinetics of heroin and its major metabolites. Clinical Pharmacokinetics, 45, 401–417.CrossRefPubMed
18.
go back to reference Cohn, G. L., Cramer, J. A., McBride, W., Brown, R. C., & Kleber, H. D. (1974). Heroin and morphine binding with human serum proteins and red blood cells. Proceedings of the Society for Experimental Biology and Medicine, 147, 664–666.PubMed Cohn, G. L., Cramer, J. A., McBride, W., Brown, R. C., & Kleber, H. D. (1974). Heroin and morphine binding with human serum proteins and red blood cells. Proceedings of the Society for Experimental Biology and Medicine, 147, 664–666.PubMed
19.
go back to reference Mitcheson, J. S., Chen, J., Lin, M., Culberson, C., & Sanguinetti, M. C. (2000). A structural basis for drug-induced long QT syndrome. Proceedings of the National Academy of Sciences of the United States of America, 97, 12329–12333.CrossRefPubMed Mitcheson, J. S., Chen, J., Lin, M., Culberson, C., & Sanguinetti, M. C. (2000). A structural basis for drug-induced long QT syndrome. Proceedings of the National Academy of Sciences of the United States of America, 97, 12329–12333.CrossRefPubMed
20.
go back to reference Sanguinetti, M. C., & Mitcheson, J. S. (2005). Predicting drug-hERG channel interactions that cause acquired long QT syndrome. Trends in Pharmacological Sciences, 26, 119–124.CrossRefPubMed Sanguinetti, M. C., & Mitcheson, J. S. (2005). Predicting drug-hERG channel interactions that cause acquired long QT syndrome. Trends in Pharmacological Sciences, 26, 119–124.CrossRefPubMed
21.
go back to reference Zünkler, B. J. (2006). Human ether-a-go-go-related (hERG) gene and ATP-sensitive potassium channels as targets for adverse drug effects. Pharmacology and Therapeutics, 112, 12–37.CrossRefPubMed Zünkler, B. J. (2006). Human ether-a-go-go-related (hERG) gene and ATP-sensitive potassium channels as targets for adverse drug effects. Pharmacology and Therapeutics, 112, 12–37.CrossRefPubMed
22.
go back to reference Milnes, J. T., Crociani, O., Arcangeli, A., Hancox, J. C., & Witchel, H. J. (2003). Blockade of hERG potassium currents by fluvoxamine: Incomplete attenuation by S6 mutations at F656 or Y652. British Journal of Pharmacology, 139, 887–898.CrossRefPubMed Milnes, J. T., Crociani, O., Arcangeli, A., Hancox, J. C., & Witchel, H. J. (2003). Blockade of hERG potassium currents by fluvoxamine: Incomplete attenuation by S6 mutations at F656 or Y652. British Journal of Pharmacology, 139, 887–898.CrossRefPubMed
23.
go back to reference Mitcheson, J. S. (2003). Drug binding to hERG channels: Evidence for a “non-aromatic” binding site for fluvoxamine. British Journal of Pharmacology, 139, 883–884.CrossRefPubMed Mitcheson, J. S. (2003). Drug binding to hERG channels: Evidence for a “non-aromatic” binding site for fluvoxamine. British Journal of Pharmacology, 139, 883–884.CrossRefPubMed
24.
go back to reference Stork, D., Timin, E. N., Berjukow, S., Huber, C., Hohaus, A., Auer, M., et al. (2007). State dependent dissociation of hERG channel inhibitors. British Journal of Pharmacology, 151, 1368–1376.CrossRefPubMed Stork, D., Timin, E. N., Berjukow, S., Huber, C., Hohaus, A., Auer, M., et al. (2007). State dependent dissociation of hERG channel inhibitors. British Journal of Pharmacology, 151, 1368–1376.CrossRefPubMed
Metadata
Title
Comparison of the Effects of Methadone and Heroin on Human ether-à-go-go-Related Gene Channels
Authors
Bernd J. Zünkler
Maria Wos-Maganga
Publication date
01-09-2010
Publisher
Humana Press Inc
Published in
Cardiovascular Toxicology / Issue 3/2010
Print ISSN: 1530-7905
Electronic ISSN: 1559-0259
DOI
https://doi.org/10.1007/s12012-010-9074-y

Other articles of this Issue 3/2010

Cardiovascular Toxicology 3/2010 Go to the issue